Literature DB >> 26141929

Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome.

Carlos J Cobeñas1, Paula S Bresso2, Laura L Lombardi2, Oscar R Amoreo2, Javier D Ruscasso2, Ana P Spizzirri2, Ângela Del C Suarez2, Javier H Zalba2, Ricardo C Rahman2, Paula Risso3.   

Abstract

BACKGROUND: We performed a retrospective evaluation of patients with diarrhea-associated hemolytic uremic syndrome (D + HUS) with the aims of: (1) determining the rate of red blood cell (RBC) transfusions; (2) establishing the relationship between need for RBC transfusion and severity of renal involvement; (3) determining whether precise measurements of lactic dehydrogenase (LDH) levels can predict the rate of hemolysis and severity of renal disease.
METHODS: A total of 288 patients with D + HUS were retrospectively divided into three groups based on dialysis treatment: group 1, no dialysis treatment (144 patients); group 2, dialysis for 1-10 days (67 patients); group 3, dialysis for ≥11 days (77 patients).
RESULTS: Of the patients in groups 1, 2 and 3, 73.6, 86.5 and 83.1%, respectively, required at least one RBC transfusion. The number of RBC transfusions in groups 1, 2 and 3 was 163, 107 and 162, respectively. Comparison of the groups revealed that the number of RBC transfusions was significantly higher in patients in groups 2 and 3 than in those in group 1 (p = 0.0001). Most RBC transfusions (94.2%) occurred during the first 2 weeks of the disease. The median peak LDH level was 2091 U/l in 32 patients with no RBC transfusion (group A), 3900 U/l in 73 patients with one transfusion (group B) and 6378 U/l in 62 patients with two or more transfusions (group C). Patients who received two or more RBC transfusions had a significantly higher median peak LDH level than those who did not receive RBC transfusions or received only one transfusion. This difference was also observed between patients who received only one RBC transfusion and those who did not receive any transfusions (p < 0.00001). Comparison of LDH levels on admission and peak LDH levels among patients in groups A, B and C revealed that 28/32 patients in group A, 56/73 patients in group B and 33/62 patients in group C had a stable LDH level, suggesting that patients with a stable LDH level require fewer RBC transfusions (p ≤ 0.006). Finally, we evaluated the possibility of an association between peak LDH levels and the degree of renal disease. The median peak LDH level in patients of group 1, 2 and 3 was 3538 (range 756-9373), 5165 (451-9205) and 7510 (1,145-16,340) U/l, respectively. Patients with >10 days of dialysis (group 3) had the highest LDH levels, followed by patients with 1-10 days of dialysis (group 2) and then by patients with no dialysis requirements (group 1) (p < 0.00001).
CONCLUSIONS: The rate of RBC transfusion was higher in patients with the most severe renal injury, and most were performed during the first 2 weeks of the disease. Patients with stable LDH levels seemed to require fewer RBC transfusions. Median peak LDH levels were significantly higher in the group of patients with the most severe renal disease.

Entities:  

Keywords:  Hemolytic uremic syndrome; Lactic dehydrogenase levels; Microangiopathic hemolytic anemia; Red blood cell transfusions; Renal disease

Mesh:

Substances:

Year:  2015        PMID: 26141929     DOI: 10.1007/s00467-015-3147-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  SERUM LACTIC DEHYDROGENASE ISOZYME PATTERNS IN CARDIOVASCULAR AND OTHER DISEASES, WITH PARTICULAR REFERENCE TO ACUTE MYOCARDIAL INFARCTION.

Authors:  L COHEN; J DJORDJEVICH; V ORMISTE
Journal:  J Lab Clin Med       Date:  1964-09

2.  THE HEMOLYTIC-UREMIC SYNDROME.

Authors:  C GIANANTONIO; M VITACCO; F MENDILAHARZU; A RUTTY; J MENDILAHARZU
Journal:  J Pediatr       Date:  1964-04       Impact factor: 4.406

3.  Epidemic hemolytic-uremic syndrome in children.

Authors:  H A Repetto
Journal:  Kidney Int       Date:  1997-12       Impact factor: 10.612

Review 4.  Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome.

Authors:  Horatio A Repetto
Journal:  Kidney Int Suppl       Date:  2005-08       Impact factor: 10.545

5.  Haemolytic uraemic syndrome associated with faecal cytotoxin and verotoxin neutralizing antibodies.

Authors:  A A Novillo; L E Voyer; R Cravioto; M C Freire; G Castaño; R Wainstein; N Binztein
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

6.  Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children.

Authors:  Ricardo C Rahman; Carlos J Cobeñas; Ricardo Drut; Oscar R Amoreo; Javier D Ruscasso; Ana P Spizzirri; Angela Del C Suarez; Javier H Zalba; Celia Ferrari; Marcela C Gatti
Journal:  Pediatr Nephrol       Date:  2011-08-02       Impact factor: 3.714

7.  Early erythropoietin in post-diarrheal hemolytic uremic syndrome: a case-control study.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2014-08-21       Impact factor: 3.714

8.  Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial.

Authors:  Lars Pape; Thurid Ahlenstiel; Martin Kreuzer; Jens Drube; Kerstin Froede; Doris Franke; Jochen H H Ehrich; Marion Haubitz
Journal:  Pediatr Nephrol       Date:  2008-12-16       Impact factor: 3.714

9.  Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis.

Authors:  Carlos J Cobeñas; Laura F Alconcher; Ana P Spizzirri; Ricardo C Rahman
Journal:  Pediatr Nephrol       Date:  2007-06-13       Impact factor: 3.714

10.  Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome.

Authors:  R Exeni; H Donato; P Rendo; M Antonuccio; M C Rapetti; I Grimoldi; A Exeni; A de Galvagni; E Trepacka; A Amore
Journal:  Pediatr Nephrol       Date:  1998-04       Impact factor: 3.714

View more
  6 in total

1.  Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.

Authors:  Alejandro Balestracci; Marina Andrea Capone; Luciana Meni Battaglia; Ismael Toledo; Sandra Mariel Martin; Laura Beaudoin; Jeanette Balbaryski; Lorena Gómez
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

Review 2.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

Review 3.  Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.

Authors:  Patrick R Walsh; Sally Johnson
Journal:  Pediatr Nephrol       Date:  2018-07-30       Impact factor: 3.714

4.  A novel model forecasting perioperative red blood cell transfusion.

Authors:  Yawen Zhang; Xiangjie Fu; Xi Xie; Danyang Yan; Yanjie Wang; Wanting Huang; Run Yao; Ning Li
Journal:  Sci Rep       Date:  2022-09-27       Impact factor: 4.996

Review 5.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Authors:  Adrien Joseph; Aurélie Cointe; Patricia Mariani Kurkdjian; Cédric Rafat; Alexandre Hertig
Journal:  Toxins (Basel)       Date:  2020-01-21       Impact factor: 4.546

6.  Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).

Authors:  Sebastian Loos; Jun Oh; Laura van de Loo; Markus J Kemper; Martin Blohm; Raphael Schild
Journal:  Pediatr Nephrol       Date:  2021-05-27       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.